hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06269237 id: 2023LTA briefTitle: Point of Care Test of LTA Level in Tear Fluid, Measured With a POCT Test, in DE Patients Following IPL Treatment overallStatus: NOT_YET_RECRUITING date: 2024-02-22 date: 2024-06-01 date: 2024-07-01 date: 2024-02-21 date: 2024-02-21 name: He Eye Hospital class: OTHER briefSummary: To quantify and compare tear levels of Intense pulsed light (IPL) and traditional dry eye clinical tests in dry eye patients before and after Intense pulsed light (IPL) treatment. conditions: Dry Eye studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 30 type: ESTIMATED name: M22 name: sham M22 measure: LTA measure: Non-invasive tear break-up time (NITBUT) measure: Fluorescein and lissamine conjunctival and cornea staining (CFS) measure: Meibomian quality measure: Tear Film Lipid Layer Score(TFLL) measure: Tear meniscus height (TMH) measure: Conjunctival hyperemia (RS score) measure: Ocular Surface Disease Index (OSDI) sex: ALL minimumAge: 18 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06269224 id: HU-FTR-KS-01 briefTitle: Examining Factors Influencing Thoracolumbar Mobility in Runners overallStatus: COMPLETED date: 2022-09-01 date: 2023-01-01 date: 2024-01-01 date: 2024-02-21 date: 2024-02-22 name: Hacettepe University class: OTHER briefSummary: The presence of to is thoracolumbar (TL) mobility a significant aspect in the context of running. Most of the factors may be related to certain kinematic parameters of the lumbopelvic-hip complex during running. conditions: Runners conditions: Mobility conditions: Fascia conditions: Range of Motion studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: CROSS_SECTIONAL count: 90 type: ACTUAL name: Participants were recreational runners who run between 20 to 50 km weekly; each one has 35 runners. measure: Myoton Assessment sex: ALL minimumAge: 30 Years maximumAge: 45 Years stdAges: ADULT facility: Hacettepe University city: Ankara state: Altındağ zip: 06100 country: Turkey lat: 39.91987 lon: 32.85427 hasResults: False
nctId: NCT06269211 id: RTS-019 briefTitle: Neoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer With EGFR Mutation and PD-L1 Positive Expression acronym: TOPLINE overallStatus: NOT_YET_RECRUITING date: 2024-03-30 date: 2027-01-31 date: 2030-01-31 date: 2024-02-21 date: 2024-02-21 name: Ruijin Hospital class: OTHER name: Guangdong Provincial People's Hospital briefSummary: The study is a prospective, open label, multicenter, single arm Phase II clinical trial, aiming to explore the use of neoadjuvant Toripalimab for clinically stage II-IIIB NSCLC patients with EGFR mutations and PD-L1 positive expression, providing a novel perspective for further improving the prognosis of NSCLC patients. This study will provide valuable information for further clinical trials of neoadjuvant Toripalimab and other immune checkpoint inhibitors in NSCLC patients with EGFR mutations and PD-L1 positive expression. conditions: Carcinoma, Non-Small-Cell Lung studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: This study has only one arm, neoadjuvant Toripalimab treatment arm. Primary endpoint is MPR. We apply the optimal design of Simon's two-stage model to calculate the sample size and set both sides α= 0.05 and power=0.8, resulting in a total sample size of 29. Among them, 10 patients will be enrolled in the first stage. If the number of MPR cases in the first stage is less than or equal to 1, the study will be terminated in the early stage; On the contrary, participants in the second stage will continue to be enrolled. If the total number of MPR cases is greater than or equal to 5 after the completion of the second stage, the study is considered positive. primaryPurpose: TREATMENT masking: NONE count: 29 type: ESTIMATED name: Toripalimab measure: Major Pathological Response (MPR) measure: Pathological Complete Response (pCR) measure: Objective Response Rate (ORR) measure: 2-year Event Free Survival (EFS) measure: 2-year Overall Survival (OS) measure: Safety (Number of Participants With Grade 3 and Higher-grade Treatment-related Adverse Events) measure: Feasibility (Number of Participants Who Finished Neoadjuvant therapy and Receive Surgery Within 3-6 Weeks After Neoadjuvant Therapies) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Guangdong Provincial People's Hospital city: Guangzhou state: Guangdong zip: 510180 country: China lat: 23.11667 lon: 113.25 facility: Ruijin Hospital, Shanghai Jiao Tong University School of Medicine city: Shanghai state: Shanghai zip: 200025 country: China lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06269198 id: WARD - SX - RCT II briefTitle: Postoperative Complications in Cancer Patients Monitored With Intelligent Continuous Monitoring System acronym: WARD-SX-RCT-II overallStatus: RECRUITING date: 2023-10-31 date: 2025-04-01 date: 2027-04-01 date: 2024-02-21 date: 2024-03-25 name: Rigshospitalet, Denmark class: OTHER name: Bispebjerg Hospital name: Hvidovre University Hospital briefSummary: The primary objective of this study is to determine the effect on complication severity of using a clinical monitoring system with automatic vital sign alerts in addition to routine monitoring versus routine monitoring alone in high-risk postoperative cancer patients within 30 days after surgery.
Other objectives include documentation of the severity of complications within seven days of surgery, frequency of serious adverse events, mortality, length of stay and delay of planned chemotherapy. conditions: Postoperative Complications conditions: Cancer, Treatment-Related studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomisation stratified by study site primaryPurpose: PREVENTION masking: DOUBLE maskingDescription: Participants will not be given information on group allocation. Care-providers will not be blinded, due to having to carry out the intervention.
Outcome assessor will be blinded to study allocation. whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 504 type: ESTIMATED name: WARD-CSS measure: Overall complication severity - 30 days measure: Overall complication severity - 7 days measure: Frequency of Serious adverse events measure: Days alive and out of hospital measure: Days alive and out of hospital measure: Time to initiation of post-operative adjuvant chemotherapy measure: Completion of post-operative adjuvant chemotherapy measure: Frequency of severe clinical complications measure: ICU admission measure: Surgical reintervention of any kind measure: Post-discharge readmission measure: Health-economic cost-effectiveness. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Copenhagen University hospital - Rigshospitalet status: RECRUITING city: Copenhagen state: Other (Non US) zip: 1665 country: Denmark name: Jesper Mølgaard, PhD role: CONTACT phone: +4535453545 email: jesper.moelgaard@regionh.dk name: Eske K Aasvang, DMSc role: CONTACT phone: +4535450802 email: eske.kvanner.aasvang.01@regionh.dk lat: 55.67594 lon: 12.56553 facility: Bispebjerg Hospital status: RECRUITING city: Copenhagen state: Other (Non US) zip: 2400 country: Denmark name: Christian S Meyhoff, PhD role: CONTACT phone: +4524910542 email: christian.sylvest.meyhoff@regionh.dk name: Christian S Meyhoff, PhD role: PRINCIPAL_INVESTIGATOR lat: 55.67594 lon: 12.56553 facility: Hvidovre Hospital status: NOT_YET_RECRUITING city: Hvidovre state: Other (Non US) zip: 2650 country: Denmark name: Katja B L Glud, RN role: CONTACT phone: +4538625713 email: katja.balle.levring.glud@regionh.dk name: Søren Kjær, MD role: PRINCIPAL_INVESTIGATOR lat: 55.65719 lon: 12.47364 hasResults: False
nctId: NCT06269185 id: 2024_IFXvsADAinUC briefTitle: Comparison Between Infliximab and Adalimumab on Patients With Ulcerative Colitis overallStatus: RECRUITING date: 2024-03-06 date: 2025-03-01 date: 2025-03-01 date: 2024-02-21 date: 2024-03-15 name: Vastra Gotaland Region class: OTHER_GOV briefSummary: Anti-TNF (tumor necrosing factor) treatment with infliximab (IFX) and adalimumab (ADA) are established first-line biological therapies used in treatment of patients with ulcerative colitis (UC). There are no head-to-head comparative studies between these two drug but meta-analysis of randomized controlled trials states that IFX might be more effective than ADA for the induction of clinical remission. However, several observational studies conclude that ADA seem to have similar effect as IFX in treating patients with UC but these studies have limitations.
The overall aim of this retrospective multicenter observational cohort study is to evaluate if there is a difference in efficacy between infliximab (IFX) and adalimumab (ADA) in treating bio-naive patients with UC in the short and long term during the modern era when therapeutic drug monitoring have been used to optimize anti-TNF treatment. conditions: Ulcerative Colitis conditions: Inflammatory Bowel Diseases studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 270 type: ESTIMATED name: Infliximab name: Adalimumab measure: Percentage of patients achieving steroid-free clinical remission measure: Percentage of patients achieving clinical response measure: Percentage of patients achieving clinical remission measure: Percentage of patients achieving biochemical remission measure: Percentage of patients achieving clinical remission measure: Percentage of patients achieving biochemical remission measure: Percentage of patients achieving endoscopic response measure: Percentage of patients achieving endoscopic remission measure: Remission rates in the subpopulations of UC-patients with severe, moderate and mild disease respectively sex: ALL minimumAge: 18 Years maximumAge: 100 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Västra Götalandsregionen status: RECRUITING city: Göteborg country: Sweden name: Börje Jonefjäll role: CONTACT phone: +46703753933 email: borje.jonefjall@vgregion.se lat: 57.70716 lon: 11.96679 hasResults: False
nctId: NCT06269172 id: 162076 id: 322453 type: OTHER domain: HRA briefTitle: Perceptions Across Ethnicities to Develop an Adapted Intervention for Breathlessness acronym: Paint overallStatus: RECRUITING date: 2024-02-12 date: 2025-11-30 date: 2025-11-30 date: 2024-02-21 date: 2024-02-21 name: University Hospitals, Leicester class: OTHER briefSummary: An individual's experience of their breathlessness is influenced by multiple factors including their medical condition, psychology, sociological and situational circumstances which will include ethnicity. There is currently a lack of evidence exploring the impact of ethnicity in the experience and presentation of breathlessness.
The non-medical management of breathlessness in respiratory diseases includes pulmonary rehabilitation (PR). PR is a highly evidenced exercise-based intervention to help manage breathlessness, improving health-related quality of life and improving survival. Recent audits in England and Wales showed 89% of patients attending PR were recorded as having a White British ethnicity which is in contrast to national ethnicity demographics. This may be because the cultural acceptability of PR components are not fully considered. Therefore, this study will explore how individuals with cardiorespiratory disease from different ethnicities from the Leicestershire population experience and manage their breathlessness through art workshops, focus groups and interviews. Informed by these results, the study team will work with individuals from under-represented ethnicities and key stakeholders to co-design adaptations of PR that may improve the management of breathlessness in underrepresented ethnicities that do not attend conventional PR programmes.
The study is funded by the Wellcome Trust as part of the Leicestershire Health Inequalities Improvement Programme at the University of Leiceste conditions: Cardiovascular Diseases studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 45 type: ESTIMATED name: intereviews measure: Art Workshops, Focus Groups and Semi-Structured Interviews measure: : Experience Based Co-design The co-development of an intervention for breathlessness for under-represented ethnicities. sex: ALL minimumAge: 18 Years maximumAge: 100 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Glenfield Hospital status: RECRUITING city: Leicester state: Leicestershire zip: LE39QP country: United Kingdom name: Holly Ms Drover role: CONTACT email: hd225@leicester.ac.uk lat: 52.6386 lon: -1.13169 hasResults: False
nctId: NCT06269159 id: ONZ-2023-0185 briefTitle: The Power of 24-hour: Co-designing Intervention Components overallStatus: RECRUITING date: 2023-09-05 date: 2025-03-31 date: 2025-03-31 date: 2024-02-21 date: 2024-02-21 name: University Hospital, Ghent class: OTHER briefSummary: Most of the existing lifestyle interventions in adults with overweight or obesity focus on one movement behavior in isolation (i.e. moderate to vigorous physical activity (MVPA)). However, recent research suggests to incorporate all movement behaviors performed in one day to explore the possible synergistic health effects of targeting more than one behavior. Moreover, more optimal 24-hour movement behavior compositions are related with better cardiometabolic health. Literature shows that adults with obesity have less optimal 24-hour compositions (8-9). Therefore it would be of interest to discover the needs related to an optimal 24-hour movement behavior intervention for a group of adults with overweight and obesity using co-design to develop an intervention.
This study will conduct a concept mapping protocol to explore the needs to of people with overweight and obesity to change their sedentary behavior into more physical activity as well to include the opinion of health care providers (HCP are physiotherapists) on the needs of their patients. conditions: Overweight and Obesity studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: OTHER count: 210 type: ESTIMATED name: Concept mapping: brainstorm name: Concept mapping: clustering and rating measure: Themes measure: Score of effectiveness measure: Score of feasibility measure: Score of modifiability sex: ALL minimumAge: 25 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ghent university Hospital status: RECRUITING city: Ghent zip: 9000 country: Belgium name: Bruno Lapauw role: CONTACT email: bruno.lapauw@uzgent.be lat: 51.05 lon: 3.71667 hasResults: False
nctId: NCT06269146 id: 806035 id: 1R61MH129380-01 type: NIH link: https://reporter.nih.gov/quickSearch/1R61MH129380-01 briefTitle: Pramipexole to Enhance Social Connections overallStatus: NOT_YET_RECRUITING date: 2024-02 date: 2025-03 date: 2025-03 date: 2024-02-21 date: 2024-02-21 name: University of California, San Diego class: OTHER name: National Institute of Mental Health (NIMH) name: New York State Psychiatric Institute briefSummary: This study seeks to understand if the medication pramipexole improves social connectedness and functioning in adults (ages 18-50) who experience anxiety or depression. The study plans to enroll 108 participants total across two sites (University of California San Diego and New York State Psychiatric Institute). Pramipexole will be given in a 6-week randomized, double-blind, placebo-controlled trial. Social reward processing will be assessed using measures of brain function (fMRI), behavior, and self-report at baseline and week 6. Knowledge gained from this study will help determine the therapeutic potential of targeting the dopamine system to remediate social disconnection as an anxiety and depression intervention. conditions: Anxiety Disorders conditions: Anxiety conditions: Depression conditions: Social Disconnection studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE maskingDescription: The pharmacy will blind drug and placebo through identical encapsulation. Placebo will match the study drug in mode of administration, color, size, and taste. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 108 type: ESTIMATED name: Pramipexole Pill name: Placebo Pill measure: Neural activation during social reward anticipation measure: Neural activation during opportunities to disclose to others measure: Motivation to engage in shared experiences with others measure: Positive affect in response to the social affiliation task measure: Social approach goals during the social affiliation task measure: Social approach behavior during the social affiliation task measure: Future approach motivation measure: Blood plasma pramipexole concentrations measure: Negative affect in response to the social affiliation task measure: Neural activation during social punishment anticipation measure: Social avoidance goals during the social affiliation task measure: Anxious behavior during the social affiliation task sex: ALL minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT facility: University of California, San Diego city: San Diego state: California zip: 92093 country: United States name: Margaret K Satchwell, BS role: CONTACT phone: 858-822-4357 email: mksatchwell@health.ucsd.edu lat: 32.71533 lon: -117.15726 facility: New York State Psychiatric Institute city: New York state: New York zip: 10032 country: United States name: Liza Handler, BS role: CONTACT phone: 917-652-6355 email: liza.handler@nyspi.columbia.edu lat: 40.71427 lon: -74.00597 hasResults: False
nctId: NCT06269133 id: R2810-ONC-22115 briefTitle: Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Patients overallStatus: ACTIVE_NOT_RECRUITING date: 2024-02-21 date: 2027-03-31 date: 2027-06-23 date: 2024-02-21 date: 2024-03-13 name: Regeneron Pharmaceuticals class: INDUSTRY briefSummary: This multi-year cohort study will assess the real-world safety and effectiveness of 1L treatment with cemiplimab in combination with platinum-doublet chemotherapy across advanced NSCLC patient subgroups defined by age, sex, race, and ethnicity. Patients will be retrospectively identified from at least two US electronic health record (EHR)-based databases. conditions: Advanced Non-small Cell Lung Cancer studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: OTHER count: 1000 type: ESTIMATED name: REGN2810 name: Platinum-doublet chemotherapy measure: Real-world response rate (rwRR) measure: Any treatment-emergent immune-mediated adverse event (imAE) measure: Any treatment-emergent imAE resulting in hospitalization measure: Any treatment-emergent imAE resulting in death measure: Specific treatment-emergent imAEs measure: Real-world duration of response (rwDOR) measure: Real-world progression-free survival (rwPFS) measure: Real-world overall survival (rwOS) measure: Treatment-emergent immune-mediated adverse events (imAEs) measure: Infusion-related reaction (IRR) measure: IRR resulting in hospitalization measure: IRR resulting in death sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Regeneron Research Facility city: Tarrytown state: New York zip: 10591 country: United States lat: 41.07621 lon: -73.85875 hasResults: False
nctId: NCT06269120 id: NN9924-7787 id: U1111-1290-8109 type: OTHER domain: World Health Organization (WHO) briefTitle: SEMA-CardioDiab HUNGARY: A Research Study to Understand the Effects of Oral Semaglutide on Blood Sugar Levels, Weight, and Cardiovascular Risk in People With Type 2 Diabetes Patients in Hungary overallStatus: NOT_YET_RECRUITING date: 2024-02-15 date: 2024-09-30 date: 2024-09-30 date: 2024-02-21 date: 2024-02-21 name: Novo Nordisk A/S class: INDUSTRY briefSummary: Participant will get oral semaglutde as prescribed by the study doctor. The study will last for about 26 ± 4 weeks (5 to 7 months). Participant will be asked to complete a questionnaire about how they take oral semaglutide tablets during normal scheduled visit with doctor. Participant will also be asked questions about health and their diabetes treatment and lab tests as part of normal doctor's appointment. conditions: Type 2 Diabetes studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 470 type: ESTIMATED name: Oral Semaglutide measure: Glycated haemoglobin (HbA1c ) reduction greater than or equal to (≥) 0.5%-point and body weight reduction ≥ 5% measure: Change in HbA1c measure: Change in fasting plasm glucose (FPG) measure: Absolute change in body weight (BW) measure: Relative change in BW measure: HbA1c less than (<) 7.0% measure: HbA1c <6.5% measure: Body weight reduction ≥5% measure: HbA1c reduction ≥1%-point and BW reduction ≥5% measure: HbA1c reduction ≥1%-point and BW reduction ≥3% measure: Change in waist circumference measure: Change in blood pressure (BP) (systolic and diastolic) measure: Change in lipid parameters (total cholesterol, low density lipoprotein cholesterol [LDL-C], high density lipoprotein cholesterol [HDL-C], triglycerides [TG]) measure: Change in high sensitive C-reactive protein (hsCRP) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06269094 id: MB-2312 briefTitle: A Study to Understand How Continuous Glucose Monitors Impact Eating Behavior overallStatus: RECRUITING date: 2024-02-14 date: 2024-05 date: 2024-05 date: 2024-02-21 date: 2024-03-13 name: Midwest Center for Metabolic and Cardiovascular Research class: OTHER briefSummary: The purpose of this study is to evaluate if and how continuous glucose monitors (CGMs) impact food consumption, choice, and purchasing in individuals attempting to lose weight using their own weight management approach. conditions: Weight Loss studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: OTHER masking: NONE count: 20 type: ESTIMATED name: CGM measure: Qualitative insights on consumer behavior sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: Biofortis, Inc. status: RECRUITING city: Addison state: Illinois zip: 60101 country: United States name: Grace Mooney, MS role: CONTACT phone: 630-617-2000 email: grace.mooney@mxns.com name: Gina Castiglione, RD role: CONTACT phone: 6306172000 email: gina.castiglione@mxns.com name: Aditi M Shah, MD role: PRINCIPAL_INVESTIGATOR lat: 41.9317 lon: -87.98896 hasResults: False